High serum YKL‐40 level after surgery for colorectal carcinoma is related to short survival

Cintin, C.; Johansen, Julia S.; Christensen, Ib Jarle; Price, Paul A.; Sørensen, Steen; Nielsen, Hans Jørgen

doi:10.1002/cncr.10644

Cited by 127 publications

(133 citation statements)

References 27 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…There was no relationship between serum YKL-40 levels and LDH and performance status of the patients. The percentage of patients with extensive SCLC with elevated serum YKL-40 is comparable to the percentage of patients with metastatic breast, colorectal and ovarian carcinoma with elevated serum YKL-40 [19][20][21][22][23][24]. The present study also showed that an elevated serum YKL-40 level at time of diagnosis reflected increased lung cancer aggressiveness since patients with high serum YKL-40 had shorter [19][20][21][22][23][24].…”

Section: Discussionsupporting

confidence: 66%

“…The present study also showed that an elevated serum YKL-40 level at time of diagnosis reflected increased lung cancer aggressiveness since patients with high serum YKL-40 had shorter [19][20][21][22][23][24]. It has also been shown that serum YKL-40 was independent of serum CEA in colorectal cancer patients [23,24], of estrogen receptor status and HER2 status in breast cancer patients [20], and of serum CA125 in ovarian cancer patients [21,22]. Cintin et al [24] found that during the follow-up of curatively operated colorectal cancer patients a high post-operative serum YKL-40 level was an independent predictor of death within the following 6 months [24].…”

Section: Discussionmentioning

confidence: 70%

“…The percentage of patients with extensive SCLC with elevated serum YKL-40 is comparable to the percentage of patients with metastatic breast, colorectal and ovarian carcinoma with elevated serum YKL-40 [19][20][21][22][23][24]. The present study also showed that an elevated serum YKL-40 level at time of diagnosis reflected increased lung cancer aggressiveness since patients with high serum YKL-40 had shorter [19][20][21][22][23][24]. It has also been shown that serum YKL-40 was independent of serum CEA in colorectal cancer patients [23,24], of estrogen receptor status and HER2 status in breast cancer patients [20], and of serum CA125 in ovarian cancer patients [21,22].…”

Section: Discussionmentioning

confidence: 99%

“…Increased serum YKL-40 levels are found in patients with primary and metastatic breast carcinoma [18][19][20] and ovarian carcinoma [21,22], and in preand post-operative samples from patients with colorectal carcinoma [23,24]. It was found in these studies that high serum YKL-40 levels were related to short recurrence-free interval and poor survival of the patients.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

High serum YKL-40 level in patients with small cell lung cancer is related to early death

et al. 2004

View full text Add to dashboard Cite

Summary YKL-40, a growth factor for connective tissue cells, is secreted by cancer cells and macrophages. Elevated serum YKL-40 in patients with metastatic carcinoma has been associated with poor prognosis. We evaluated serum YKL-40 in 131 patients with small cell lung cancer (SCLC). Twenty-two percent of the patients with limited disease and 40% of the patients with extensive disease had elevated serum YKL-40. The median survival was 5.1 months for patients with elevated serum YKL-40 and 9.0 months for patients with normal serum YKL-40. Patients with elevated serum YKL-40 had increased hazard for death within the first 6 months after the start of chemotherapy compared to patients with normal serum YKL-40 (HR = 2.06, P = 0.009). Multivariate Cox analysis including routine prognostic variables showed that serum YKL-40 (P = 0.02) is independent of prognostic variables for survival within the first 6 months. Studies are needed to determine the function of YKL-40 in SCLC.

show abstract

Section: Discussionsupporting

confidence: 66%

Section: Discussionmentioning

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

High serum YKL-40 level in patients with small cell lung cancer is related to early death

et al. 2004

View full text Add to dashboard Cite

show abstract

“…The role of YKL40 in cancer cells is still unclear, but several promising functions have been proposed. 9 Elevated serum YKL40 levels were found in several primary and metastatic malignancies and serum YKL40 may serve as a valuable and independent prognostic biomarker of short survival. 10 Golgi protein 73 (GP73), also named golgi phosphoprotein 2 (GOLPH2), is a 400 amino acid, 73 kDa trans-membrane glycoprotein that normally resides within the cis-golgi complex.…”

mentioning

confidence: 99%

Diagnostic performance of alpha-fetoprotein, YKL40 and GP73 in hepatocellular carcinoma Egyptian patients

et al. 2016

View full text Add to dashboard Cite

INTRODUCTIONHepatocellular carcinoma (HCC) is the fifth most common malignancy in the world with high morbidity and mortality but its pathogenesis remains unclear. 1Because primary liver cancer is a growing concern showing poor prognosis due to its rapid infiltrating power and complicating liver cirrhosis; more attention were given to address the causal risk factors that could be preventable and/or treatable. 2HCC is phenotypically and genetically heterogeneous tumor, reflecting in part the heterogeneity of etiologic factors involved in (i) the onset of HCC development that is also influenced by age, gender and ethnic differences, (ii) the complexity of hepatocyte functions and epigenome leading to neo-plastic transformation and (iii) the late stage of HCC development. Methods:This study aimed to compare the diagnostic performance of AFP, YKL40 and GP73 in patients' serum with hepatocellular carcinoma (HCC) in high-risk population in an attempt to justify the new, sensitive, specific and rapid measure for the diagnosis and detection of HCC. Serum YKL40, GP73 and alpha-fetoprotein (AFP) were compared in a total of 60 human subjects in this study, including 20 healthy adults, and 40 patients with HCC, The main outcome measures were the specificity and sensitivity of YKL40 and GP73 in patients at risk for the development of HCC. Results: Using 4.4 relative units as a cut-off value, the sensitivity and specificity of serum GP73 for HCC were 85% and 90% compared with 77% and 60% for YKL40 using 21.06 ng/ml as a cut-off value. On the same context, the sensitivity and specificity of serum AFP at 8.5ng/ml cut-off were 82% and 95%. While that for the AFP and GP73 combined detection was up to 92% and 96%, justifying that the combined detection could prevent the false negative diagnosis by any marker alone and significantly improve the detection rate of HCC. Conclusions: The current evidence indicates that serum GP73 has HCC diagnostic efficacy inferior to that of AFP and YKL40 and the clinical implementation of serum GP73 measurement as a standard test for HCC is recommended alone or in combination with AFP.

show abstract

YKL‐40 and MMP‐9 as serum markers for patients with primary central nervous system lymphoma

Hottinger

Iwamoto

Karimi

et al. 2011

Annals of Neurology

View full text Add to dashboard Cite

show abstract

High serum YKL‐40 level after surgery for colorectal carcinoma is related to short survival

Cited by 127 publications

References 27 publications

High serum YKL-40 level in patients with small cell lung cancer is related to early death

High serum YKL-40 level in patients with small cell lung cancer is related to early death

Diagnostic performance of alpha-fetoprotein, YKL40 and GP73 in hepatocellular carcinoma Egyptian patients

YKL‐40 and MMP‐9 as serum markers for patients with primary central nervous system lymphoma

Contact Info

Product

Resources

About